Diffuse interstitial lung disease linked to vandetanib

Clin Lung Cancer. 2012 May;13(3):236-8. doi: 10.1016/j.cllc.2011.10.004. Epub 2011 Dec 1.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / complications
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / physiopathology
  • Disease-Free Survival
  • Drug Hypersensitivity / complications*
  • Drug Hypersensitivity / drug therapy
  • Drug Hypersensitivity / physiopathology
  • Drug Substitution
  • Humans
  • Idiopathic Pulmonary Fibrosis / chemically induced*
  • Idiopathic Pulmonary Fibrosis / drug therapy
  • Idiopathic Pulmonary Fibrosis / physiopathology
  • Lung Neoplasms / complications
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / physiopathology
  • Male
  • Middle Aged
  • Piperidines / administration & dosage
  • Piperidines / adverse effects*
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects*
  • Quinazolines / administration & dosage
  • Quinazolines / adverse effects*
  • Spirometry
  • Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*

Substances

  • Piperidines
  • Protein Kinase Inhibitors
  • Quinazolines
  • Vascular Endothelial Growth Factor Receptor-2
  • vandetanib